DB289
Phase 2Small molecule
DB289 is one of 29 small molecule programs targeting Malaria. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
479 competitors in Malaria
#DrugCompanyPhaseTrials
1Biltricide
BayerPreclinical
Stelara
Johnson & JohnsonPreclinical
DB289
IImmtech Pharmaceuticals, Inc
Phase 2
Hydroxychloroquine Sulfate
NovartisPreclinical
Iron
WWatson Pharmaceuticals
Preclinical
IV LBH589
NovartisPreclinical
Mefloquine Plus Artesunate
Medicines for Malaria VenturePreclinical
IV Ceftriaxone
RRESnTEC, Institute of Research
Preclinical
RTS,S/AS01E
GSKPreclinical
Malarone
Medicines for Malaria VenturePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DB289. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IImmtech Pharmaceuticals, Inc